Kornimate/medical-research-clean huggingface dataset:
a comparison of the visual performance of trifocal versus extended depth of focus intraocular lenses

Conditions: Cataract; Lenses; Visual Impairment

Summary: we are conducting a trial evaluating the performance of trifocal versus extended depth of focus intraocular lenses. these lenses will be implanted in otherwise healthy individuals with visual problems due to bilateral cataracts. patients must be seeking an improvement in their visual performance with a special focus on presbyopia correction.

to compare the clinical performance, quality of vision and subjective outcomes between the extended depth of focus (edof) mini well ready intraocular lens (iol) and the diffractive trifocal panoptix iol, at 3 months following second eye implantation. statistical analysis all data will be analyzed using the statistical package for the social sciences (spss) v23 (spss inc., chicago, il, usa). graphs will be made using spss and microsoft excel (microsoft corp., redmond, wa, usa). normality will be tested for using the shapiro wilk test. if the data is normal, an independent t test will be used for comparing the continuous variables between the groups. if the data is not normal, then we will utilize the mann whitney u test. sample size calculation the sample size calculation was based on the mean binocular uncorrected near visual acuity (unva) tested at 40cm under photopic condition. a previous study on the same diffractive trifocal iol revealed a binocular unva of 0.01 ± 0.087 logmar (12). the anticipated mean value for mini well toric ready is 0.10 logmar. based on these assumptions, an alpha of 0.05 and power of 0.8, it was calculated a number of 15 patients implanted bilaterally for each group. assuming a dropout rate of 20% on the primary outcome measure, this resulted in a total number of 36 bilateral patients, 18 each group. duration of the project: six months to one year

Eligibility criteria:
inclusion criteria: * patient aged 30 years of age or older * has bilateral cataracts with visual problems * is motivated for vision correction exclusion criteria: * any ocular pathology that could impair vision, for example: * pseudoexfoliation syndrome * zonular weakness * retinal or corneal dystrophies * retinal pathologies like age related macular degeneration * history of trauma * history of ocular surgery * individuals having trouble understanding written or spoken language * those with dense cataracts causing problems with optical biometry * average corneal powers outside the range of 41 diopters (d) to 46 d * corneal astigmatism \> 0.75 d * irregular astigmatism index of 0.54 or higher

Keywords: cataract intraocular lenses trifocal intraocular lenses extended depth of focus intraocular lenses presbyopia
cisplatin, capecitabine, gemcitabine and epirubicin or docetaxel for patients with stage iii or iv pancreatic cancer

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy, such as cisplatin, capecitabine, gemcitabine hydrochloride, epirubicin hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more tumor cells. it is not yet known whether cisplatin, capecitabine, and gemcitabine hydrochloride are more effective when given together with epirubicin hydrochloride or docetaxel in treating patients with advanced or metastatic pancreatic cancer. purpose: this randomized phase ii trial is studying the side effects of giving cisplatin, capecitabine, and gemcitabine hydrochloride together with epirubicin hydrochloride compared with giving cisplatin, capecitabine, and gemcitabine hydrochloride together with docetaxel and to see how well it works in treating patients with stage iii or stage iv pancreatic cancer.

objectives: * assess 6-months progression-free survival of patients with stage iii or iv adenocarcinoma of the pancreas treated with cisplatin, capecitabine, gemcitabine hydrochloride (pxg) and epirubicin hydrochloride vs pxg and docetaxel. * evaluate the activity and toxicity of these regimens in these patients. outline: this is a multicenter study. patients are randomized to 1 of 2 arms. * arm i (pexg): patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. * arm ii (pgdx): patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. patients may then undergo surgery if the tumor becomes resectable.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the pancreas * stage iii or iv disease * measurable disease * no symptomatic brain metastases patient characteristics: * karnofsky performance status 60-100% * adequate bone marrow, liver, and kidney function * not pregnant or nursing * no other malignancies within the past 5 years except surgically treated carcinoma in situ of the cervix, and basal or squamous cell carcinoma of the skin * no multiple severe diseases that can compromise study safety, including any of the following: * cardiac failure * myocardial infarction within the past 4 months * cardiac arrhythmia * history of psychiatric disabilities prior concurrent therapy: * no prior chemotherapy or radiotherapy for pancreatic cancer * no other concurrent experimental drugs

Keywords: adenocarcinoma of the pancreas stage iii pancreatic cancer stage iv pancreatic cancer
arm function and quality of life following mastectomy.

Conditions: Breast Cancer

Summary: to measure arm function and quality of life of mastectomy patients.

treatment: randomized to one of two treatment arms. group one: basic active exercise program at home. group two: instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises. range of motion measurements will be taken at the first session, 1 month, 6 weeks, 3 months, 6 months and 1 year. patients will complete demographic form, functional questionnaire, and qol questionnaire.

Eligibility criteria:
inclusion criteria: * patients who have been referred from unmh to crtc for further treatment following mastectomy/lumpectomy surgery. exclusion criteria: * not specified

Keywords: supportive mastectomy quality of life arm function
non-invasive brain stimulation paired with fes cycling post sci

Conditions: Incomplete Spinal Cord Injury

Summary: this project is randomized controlled trial which will explore the effect of pairing repetitive transcranial magnetic stimulation (rtms) with functional electrical stimulation (fes) cycling on lower extremity function in people with incomplete spinal cord injury and compare the effects to each one of these interventions alone.

following a spinal cord injury, people often have decreased strength and balance in their legs, making it difficult to walk. to improve leg function in people with spinal cold injuries, the investigators can use electrical stimulation on muscles while participants are cycling to increase the muscle activation and nerve connections. another way to improve the nerve connections to the muscles is by stimulating the brain directly. previous research has looked at the effects of each of these treatments, but they have not been used together. in this study, the investigators will pair both electrical stimulation on the legs during cycling with brain stimulation or a sham brain stimulation to improve recovery and determine if using these methods together results in better outcomes, such as increased walking speed. participants will attend training sessions for six weeks, twice per week. each person will first receive the active or sham brain stimulation at the beginning of the session for 30 minutes and then they will receive the electrical stimulation on their legs while cycling for 60 minutes. participants will be evaluated before the start of the treatment, in the middle of the study, at the final session, and again two weeks after the last session of the treatment. assessments will include clinical tests of gait, balance, and strength. inertial measurement units (imu) and a pressure sensor gait mat will be used to evaluate the gait and balance parameters.

Eligibility criteria:
inclusion criteria: * adult * having motor incomplete sci with level c or d on the american spinal injury association impairment scale (ais) with the lesion at any level of the cord resulting from either traumatic or non-traumatic etiology who are at least one-year post-injury. * having non-progressive sci * being able to walk independently for 10 meters without help from another person exclusion criteria: * other orthopedic or neurological implications that affect the lower extremity function * contraindications to fes (e.g., implanted electronic devices, unhealed bone fractures, sever contractures, extreme osteoporosis or osteoarthritis) * contraindications to rtms (e.g., metal implants, history of seizure, cochlear implants)

Keywords: incomplete spinal cord injury repetitive transcranial magnetic stimulation functional electrical stimulation cycling lower extremity function walking speed muscle strength feasibility
methylation pattern and pain sensation in children with intellectual disability

Conditions: Intellectual Disability

Summary: previous literature data indicate that children with intellectual disability (id) experience more severe pain and more frequently than their cognitively healthy peers, during their daily life. repeated and chronic pain exposure triggers a vicious circle of hyperalgesia and reduction of the impaired cognitive and adaptive function. furthermore, these children are unable to rationalize any intervention targeted to contain potentially painful actions. epigenetics studies mechanisms responsible for a set of modifications that regulate gene expression without altering the dna sequence itself. dna methylation and posttranslational modification of histones are the main epigenetic mechanisms. it is widely accepted that these mechanisms can be engaged by environmental experience, such as early life trauma, pain or addiction leading to the idea of epigenetics as 'a bridge' between genes and environment. several epigenetic studies evaluated genes coding proteins involved in recycling of neurotransmitters (scl6a4), in transmission of painful stimuli (trpa1) and in response to analgesics (oprm1). in particular, some studies assessed trpa1 gene, coding for a cationic channel responsible for the transmission of thermal-painful sensations, and scl6a4, a serotonin-recycling transmembrane protein presents at inter-synaptic level, have highlighted the importance of methylation in a pathological experience of chronic pain and anxiety disorder in the adult population. opioid receptor oprm1 is involved in the endogenous and exogenous opioid-mediated analgesia and a recent work in a group of adolescents treated for idiopathic scoliosis highlights a link between greater pain post-surgery and methylation of this gene. in this context, children with id are at greater risk of undertreatment both for the difficulty in pain recognition and for the fear of medication-adverse reactions. the epigenetic study of the aforementioned genes in children with id associated with an evaluation of painful experiences and clinical history, could help understanding a scenario that it is still complex nowadays before the eyes of parents and caregivers and healthcare workers.the finding of a different methylation pattern in children with id could in part explain the different pain experience.


Eligibility criteria:
inclusion criteria: - children with scheduled venipuncture or venous cannulation for diagnostic or therapeutic reasons, with and without severe intellectual disability. exclusion criteria: - presence of autism spectrum disorder (asd) according to dsm-v criteria.

Keywords: pain intellectual disability epigenetics
iris ultimaster cohort in the iris-des registry

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate the relative effectiveness and safety of ultimaster stent compared to other drug eluting stents.


Eligibility criteria:
inclusion criteria: * age 19 and more * intervention with ultimaster stent * agreed with written informed consent form exclusion criteria: * intervention with ultimaster stent and other drug eluting stent at the same time * life expectancy of 1year and under * cardiac shock

Keywords: real world data percutaneous coronary intervention drug eluting stent
prospective observational study on incidence of invasive fungal infections among patients with acute lymphoblastic leukemia ph-negative

Conditions: Acute Lymphoblastic Leukemia, Adult; Invasive Fungal Infections

Summary: the study aims to evaluate incidence of invasive antifungal infections among patients with acute lymphoblastic leukemia ph negative during the first weeks of treatment


Eligibility criteria:
inclusion criteria: * diagnosis of acute lymphoblastic leukemia ph negative * age more than 18 yo exclusion criteria: * diagnosis of acute lymphoblastic leukemia ph positive * acute lymphoblastic leukemia relapsed/refractory * lymphoblastic lymphoma
study to assess the efficacy and safety of fk506 combined with mycophenolate mofetil (mmf) in lupus nephritis (iii/iv/v)

Conditions: Lupus Nephritis

Summary: this is an open, prospective study to assess the efficacy and safety of tacrolimus (fk506) combined with mmf in the treatment of class iii, iv, v + iv or v + iii lupus nephritis.

1. to assess the efficacy of fk506 combined with mmf vs intravenous ctx pulses in treatment of class ⅲ, ⅳ, ⅴ + ⅳ or ⅴ + ⅲ ln. 2. to investigate the safety and tolerability of fk506 combined with mmf vs intravenous ctx pulses in the treatment of class ⅲ, ⅳ, ⅴ + ⅳ or ⅴ + ⅲ ln. 3. to explore the dosing of fk506 combined with mmf and their effective range of blood concentration.

Eligibility criteria:
inclusion criteria: 1. female patients with a diagnosis of systemic lupus erythematosus (sle) according to the criteria of american rheumatic association, 1982, aged between 12-50 years, with score of sle-dai (disease active index) of more than 12 (not including class v ln). 2. patients diagnosed according to isn/rps 2003 classification criteria: class ⅲ, ⅳ, ⅳ + ⅴ, ⅲ + ⅴ ln by renal biopsy within 3 months, ci\< 4，scr\< 3 mg/dl. 3. patients with a proteinuria ≥ 1.5 g/24h, or active urine sediment. 4. patients who signed written informed consent forms (patients less than 18 years old with their parents/legal representative' signatures), and have given their consent to follow all study procedures and follow-ups. exclusion criteria: 1. patients who have received treatment of cytotoxic drugs such as cyclophosphamide (ctx), cyclosporine a for more than 1 week within three months. 2. patients with serum creatinine ≥ 3 mg/dl（265 μmol/l). 3. patients with severe infection or central nervous system symptoms. 4. patients who have impaired liver function, with alt/gpt or ast/got twice more than the normal upper limit or who have active hepatitis. 5. patients who have abnormal blood glucose, with a fasting blood glucose \> 6.2 mmol/l or post meal blood glucose \> 11.2 mmol/l. 6. patients who are pregnant or lactating. 7. patients who are known to be allergic to a macrolide.

Keywords: tacrolimus mycophenolate mofetil cyclophosphamide lupus nephritis treatment
additional effects of sternocleidomastoid release with snags in the management of cervicogenic headache

Conditions: Cervicogenic Headache

Summary: cervicogenic headache is a common type of headache in adults which causes disability and difficulty in everyday activities. according to the latest international headache society model, cervicogenic headache (cgh) is a secondary headache having c1-c2 dysfunction. snags are highly effective in the treatment approach for these patients. sternocleidomastoid muscle receive overactive tension from forward neck posture, increasing muscular fatigue and tone of muscles. this tension in scm causes referred pain in the head and neck region. snags are very effective but musculoskeletal impairments especially the tightness of sternocleidomastoid muscle still persist and can exacerbate symptoms. manual therapy targeted to the scm muscle may be effective for reducing headache and neck pain intensity and increasing performance of deep cervical flexors. findings of this study will aid the therapists in choosing which technique to use while treating the patients. this will save therapist's time and effort as they will not be using the less effective treatment protocol. furthermore, patient's time and investment will be used in the right direction.


Eligibility criteria:
inclusion criteria: * age group: 18-45 years old * both males and females * unilateral headache with no shift of side * c1-c2 dysfunction * positive flexion rotation test (rotation restriction is greater than 10 degrees) * headache at least once a month in the last 3 months * headache with at least 4 score in nprs (sign and symptoms of neck involvement) * headache with restriction of rom in the neck * headache precipitated by: sustained neck movements, and awkward head positioning. external pressure over upper cervical or occipital region headache characteristics: * moderate-severe, non-throbbing pain, usually starting in the neck. * episodes of varying duration, or: fluctuating, continuous pain exclusion criteria: * headache of non-cervical origin * diagnosed cases of:cervical spondylosis,cervical radiculopathy/ nerve root involvement/ disc herniation,cervical instability/ fracture,vertebrobasilar insufficiency ,cervical spine surgery,cervical spondylolisthesis,spinal infection or tumors,osteoporosis,history of trauma,rheumatoid arthritis,inflammatory arthritis
effects of family sodium watcher program on outcomes in heart failure patient-family caregiver dyads

Conditions: Heart Failure

Summary: the family sodium watcher program in this study is designed to improve adherence to a sodium restricted diet in patients with hf using strategies that educate both patients and family caregivers about sodium monitoring and that stress a gradual progressive adaptation to low sodium food for both patients and family caregivers.

heart failure (hf) emerged as a significant public health threat in the 1990s and has now reached epidemic proportions. despite advances in the medical treatment of hf, patients with hf face frequent hospitalizations for acute exacerbations. inadequate self-care strategies, in particular non-adherence to a sodium restricted diet (srd), is a main cause of these rehospitalizations. prior interventions to increase adherence have focused on increasing knowledge about restricting sodium in the diet have met with limited success. unaddressed by these interventions are the major barriers of measuring and tracking daily sodium intake, family members who continue to eat high sodium diets, and a preference for salty foods-particularly in the elderly who have a decreased sense of taste. it is possible to retrain the taste buds to enjoy low salt foods by gradually reducing the amount of sodium in foods over the course of 16 weeks. this retraining works best with direct involvement and support from family members. the family sodium watcher program (family swap) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. the intervention is designed to improve adherence to a srd by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods.

Eligibility criteria:
inclusion criteria: eligible patients will: * have diagnosis of chronic hf with either preserved or reduced ejection fraction * have a dedicated primary family caregiver * be able to speak and write english eligible caregivers will: * be a primary caregiver identified by the patient * the spouse, committed partner, or family member living with the hf patient * be able to speak and understand english * have no obvious major clinical cognitive impairment that would impair ability to give informed consent * have no major co-morbidities (i.e. hf, cancer, renal/liver failure, or uncontrolled diabetes as determined by self-report). exclusion criteria: patients will be excluded if they have: * major clinical cognitive impairment (i.e., dementia, alzheimer disease, and severe stroke) * a co-existing terminal illness (e.g., cancer) * a referral for heart transplantation * a dietary prescription that prevents following a 2-3 gram sodium diet (e.g., clinician does not support use of a srd). * no dedicated caregivers

Keywords: diet, low-sodium caregivers
adamts-13 and von willebrand factor levels and activities in children with cirrhosis and/or portal hypertension

Conditions: Coagulation Disorder; Cirrhosis, Liver

Summary: hemostasis-related disorders are common in cirrhosis and portal hypertension. however, it is not known whether the net effect of changes in hemostasis in the sense of predisposition to hemorrhagic or thrombotic state. it is suggested that increasing the concentration and activities of von willebrand factor (vwf) and decline adamts-13 (a disintegrin and metalloproteinase with trombospondin type 1 motif, member 13) may cause thrombophilic changes in cirrhosis and portal hypertension. the aim of this study was to investigate the changes in adamts-13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) and von willebrand factor (vwf) levels and activities in patients with cirrhosis and portal hypertension.

patients of 3 months to 18 years of age, followed-up or newly diagnosed in pediatric gastroenterology unit, who had cirrhosis or non cirrhotic portal hypertension included to the study. written informed consent obtained from the parents and/or patients. the subjects was grouped in three. the first group consisted of patients with cirrhosis (with or without portal hypertension). the second group consisted of patients with non-cirrhotic portal hypertension (developed due thrombosis of portal vein). the last group consisted of healthy volunteers. 2 ml of edta blood was taken from the patients and healty volunters. samples will be tested for vwf and adamts-13 levels and activities at the end of the study. the clinical scoring methods, peld, meld and child pugh scores, treatments received by patients, data from endoscopic, radiological screening, and blood analysis of patients were recorded.

Eligibility criteria:
inclusion criteria: • patients with cirrhosis or portal hypertension aged 3 months to 18 years. exclusion criteria: * being treated with fresh frozen plasma in the recent month. * patients previously diagnosed with bleeding diathesis. * the patients who consumed vitamin k in the recent three weeks. * patients previously diagnosed with another chronic disease (such as renal failure, heart failure etc). * patients who suffer from acute or chronic infectious diseases.

Keywords: von willebrand factor adamts-13 children cirrhosis portal hypertension